Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stop Atherosclerosis in Native Diabetics Study
Brief Summary: Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness, and reduce clinical cardiovascular events such as heart attacks and strokes. This study is a randomized 3-year trial. The primary endpoint will be a combination of various measures of the carotid artery, (which is an easy, non-invasive way to detect cardiovascular disease) and events such as heart attacks and strokes. The study will also look at secondary endpoints such as how well the heart pumps, fat,protein and inflammatory markers in the blood,and kidney function. The study enrolled 549 American Indian men and women with diabetes, \> 40 years of age and is being conducted in four field centers involving Indian Health Service/Tribal primary care facilities in Phoenix/Sacaton, Arizona; Chinle, Arizona; Rapid City/Pine Ridge, South Dakota; and Lawton, Oklahoma, with input from American Indian physicians and community members.


Options:
A: Arm Label: Extended release niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: extended release niacin, Drug: ezetimibe | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: ezetimibe | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Extended release niacin | Intervention Type: DRUG; Name: ezetimibe; Assigned to Arm(s): Extended release niacin, Ezetimibe
B: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe, Drug: Niaspan, Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Procedure: Percutaneous transluminal angioplasty (PTA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Statin therapy, Behavioral: Standard care, Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo Niaspan, Drug: Placebo Ezetimibe, Procedure: Percutaneous transluminal angioplasty (PTA) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo Niaspan; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Ezetimibe; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: MK0653, ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: statins; Assigned to Arm(s): N/A

Answer: B